---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-033289"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2026-07-15T12:30:36+00:00"
generated_at: "2026-07-15T12:35:05.893007+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma reports zero Grade 3+ toxicities from ENV-105 in Phase 1 NSCLC trial

## Summary
- Zero Grade 3+ toxicities from ENV-105 in 13 patients with advanced EGFR-mutated NSCLC.
- ENV-105 (carotuximab) combined with osimertinib (Tagrisso) shows clean safety profile.
- Targets $10B drug resistance market; no FDA-approved agent to reverse osimertinib resistance.
- Phase 1 trial ongoing; safety data supports continued development toward efficacy readout.

## SEC filing metadata
- accession: 0001493152-26-033289
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2026-07-15T12:30:36+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315226033289/0001493152-26-033289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315226033289/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-033289
- JSON: https://secwatch.observer/filing/0001493152-26-033289.json
- Plain text: https://secwatch.observer/filing/0001493152-26-033289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.